Published in AIDS Behav on December 16, 2008
Appropriateness of hydroxyethylcellulose gel as a placebo control in vaginal microbicide trials: a comparison of the two control arms of HPTN 035. J Acquir Immune Defic Syndr (2013) 1.33
Biological markers of sexual activity: tools for improving measurement in HIV/sexually transmitted infection prevention research. Sex Transm Dis (2013) 1.24
Acceptability and use of the diaphragm and Replens lubricant gel for HIV prevention in Southern Africa. AIDS Behav (2009) 1.08
Vaginal practices and associations with barrier methods and gel use among Sub-Saharan African women enrolled in an HIV prevention trial. AIDS Behav (2010) 1.08
'It's not about money, it's about my health': determinants of participation and adherence among women in an HIV-HSV2 prevention trial in Johannesburg, South Africa. Patient Prefer Adherence (2012) 0.86
Change in condom and other barrier method use during and after an HIV prevention trial in Zimbabwe. J Int AIDS Soc (2010) 0.81
Diaphragm used with replens gel and risk of bacterial vaginosis: results from a randomized controlled trial. Infect Dis Obstet Gynecol (2012) 0.76
Towards an improved investment approach for an effective response to HIV/AIDS. Lancet (2011) 11.89
Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet (2002) 11.02
Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med (2015) 9.20
Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 7.93
Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet (2007) 7.22
Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med (2008) 6.00
Hormonal contraception and the risk of HIV acquisition. AIDS (2007) 5.05
Short-course antiretroviral therapy in primary HIV infection. N Engl J Med (2013) 4.82
Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study. Lancet HIV (2015) 4.33
Direct access to emergency contraception through pharmacies and effect on unintended pregnancy and STIs: a randomized controlled trial. JAMA (2005) 4.32
Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women. J Infect Dis (2008) 3.98
PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet (2010) 3.90
Next steps for research on hormonal contraception and HIV. Lancet (2013) 3.70
Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med (2010) 3.14
Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS (2011) 2.86
Biomarker validation of reports of recent sexual activity: results of a randomized controlled study in Zimbabwe. Am J Epidemiol (2009) 2.57
Microbicide acceptability research: current approaches and future directions. Soc Sci Med (2005) 2.54
Invited commentary: condom effectiveness-will prostate-specific antigen shed new light on this perplexing problem? Am J Epidemiol (2003) 2.45
Incident and prevalent herpes simplex virus type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe. AIDS (2007) 2.35
Incidence of HIV-1 dual infection and its association with increased viral load set point in a cohort of HIV-1 subtype C-infected female sex workers. J Infect Dis (2004) 2.29
Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. AIDS (2010) 2.23
Antiretroviral therapy refusal among newly diagnosed HIV-infected adults. AIDS (2011) 2.21
Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS (2012) 2.19
Factors associated with lack of viral suppression at delivery among highly active antiretroviral therapy-naive women with HIV: a cohort study. Ann Intern Med (2015) 2.13
Combination HIV prevention. Lancet (2008) 2.10
Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol (2002) 1.97
Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women. Lancet Infect Dis (2002) 1.88
Bacterial vaginosis and vaginal yeast, but not vaginal cleansing, increase HIV-1 acquisition in African women. J Acquir Immune Defic Syndr (2008) 1.80
HIV incidence among women of reproductive age in Malawi and Zimbabwe. Sex Transm Dis (2006) 1.75
Disentangling contributions of reproductive tract infections to HIV acquisition in African Women. Sex Transm Dis (2009) 1.73
Children's perspectives on their relationships with their nonresident fathers: influences, outcomes and implications. J Child Psychol Psychiatry (2004) 1.68
Plasma and cervical viral loads among Ugandan and Zimbabwean women during acute and early HIV-1 infection. AIDS (2010) 1.68
Assessing the reporting of adherence and sexual activity in a simulated microbicide trial in South Africa: an interview mode experiment using a placebo gel. AIDS Behav (2011) 1.68
Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses (2003) 1.68
Who gets tested for HIV in a South African urban township? Implications for test and treat and gender-based prevention interventions. J Acquir Immune Defic Syndr (2011) 1.67
In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res (2009) 1.66
Acceptability of Carraguard vaginal gel use among Thai couples. AIDS (2006) 1.65
The association between Mycoplasma genitalium and HIV-1 acquisition in African women. AIDS (2012) 1.64
HIV testing and counseling leads to immediate consistent condom use among South African stable HIV-discordant couples. J Acquir Immune Defic Syndr (2013) 1.64
Better than nothing or savvy risk-reduction practice? The importance of withdrawal. Contraception (2009) 1.62
Many vaginal microbicide trial participants acknowledged they had misreported sensitive sexual behavior in face-to-face interviews. J Clin Epidemiol (2008) 1.60
Type-specific cervico-vaginal human papillomavirus infection increases risk of HIV acquisition independent of other sexually transmitted infections. PLoS One (2010) 1.55
International survey on variations in practice of the management of the third stage of labour. Bull World Health Organ (2003) 1.50
HIV and STD risk behavior among 18- to 25-year-old men released from U.S. prisons: provider perspectives. AIDS Behav (2003) 1.50
5-Aza-2'-deoxycytidine increases sialyl Lewis X on MUC1 by stimulating β-galactoside:α2,3-sialyltransferase 6 gene. Int J Biochem Cell Biol (2010) 1.48
Pregnancy and the risk of HIV-1 acquisition among women in Uganda and Zimbabwe. AIDS (2007) 1.45
Progress, challenges, and new opportunities for the prevention of mother-to-child transmission of HIV under the US President's Emergency Plan for AIDS Relief. J Acquir Immune Defic Syndr (2012) 1.44
The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli. J Biol Chem (2002) 1.44
Hormonal contraception and the risk of HIV acquisition among women in South Africa. AIDS (2012) 1.41
Unreported antiretroviral use by HIV-1-infected participants enrolling in a prospective research study. J Acquir Immune Defic Syndr (2014) 1.40
Comparative study between single dose 600 microg and repeated dose of oral misoprostol for treatment of incomplete abortion. Contraception (2004) 1.39
Effectiveness and acceptability of medical abortion provided through telemedicine. Obstet Gynecol (2011) 1.39
Audio computer-assisted self-interviewing in reproductive health research: reliability assessment among women in Harare, Zimbabwe. Contraception (2006) 1.37
Self-induction of abortion among women in the United States. Reprod Health Matters (2010) 1.35
Predictors of diaphragm use as a potential sexually transmitted disease/HIV prevention method in Zimbabwe. Sex Transm Dis (2005) 1.34
Appropriateness of hydroxyethylcellulose gel as a placebo control in vaginal microbicide trials: a comparison of the two control arms of HPTN 035. J Acquir Immune Defic Syndr (2013) 1.33
Safety and acceptability of the candidate microbicide Carraguard in Thai Women: findings from a Phase II Clinical Trial. J Acquir Immune Defic Syndr (2006) 1.30
Epidemiological synergy of Trichomonas vaginalis and HIV in Zimbabwean and South African women. Sex Transm Dis (2010) 1.29
Combined impact of sexual risk behaviors for HIV seroconversion among women in Durban, South Africa: implications for prevention policy and planning. AIDS Behav (2011) 1.28
The effects of injectable hormonal contraceptives on HIV seroconversion and on sexually transmitted infections. AIDS (2012) 1.26
A randomized, placebo-controlled trial to assess the safety and acceptability of use of carraguard vaginal gel by heterosexual couples in Thailand. Sex Transm Dis (2008) 1.26
Range of normal neutrophil counts in healthy zimbabwean infants: implications for monitoring antiretroviral drug toxicity. J Acquir Immune Defic Syndr (2006) 1.26
Sexual risk behavior among youth with perinatal HIV infection in the United States: predictors and implications for intervention development. Clin Infect Dis (2012) 1.26
Oral and injectable contraception use and risk of HIV acquisition among women in sub-Saharan Africa. AIDS (2013) 1.25
Combination antiretroviral use and preterm birth. J Infect Dis (2012) 1.25
Development of methods for cross-sectional HIV incidence estimation in a large, community randomized trial. PLoS One (2013) 1.24
Cervical inflammation and immunity associated with hormonal contraception, pregnancy, and HIV-1 seroconversion. J Acquir Immune Defic Syndr (2014) 1.23
Methodological lessons from clinical trials and the future of microbicide research. Curr HIV/AIDS Rep (2013) 1.22
Provision of antiretroviral therapy in South Africa: unique challenges and remaining obstacles. J Infect Dis (2007) 1.20
Androgen-regulated processing of the oncomir miR-27a, which targets Prohibitin in prostate cancer. Hum Mol Genet (2012) 1.19
Increased regression and decreased incidence of human papillomavirus-related cervical lesions among HIV-infected women on HAART. AIDS (2012) 1.19
RanBPM, a nuclear protein that interacts with and regulates transcriptional activity of androgen receptor and glucocorticoid receptor. J Biol Chem (2002) 1.18
Substantial regional differences in human herpesvirus 8 seroprevalence in sub-Saharan Africa: insights on the origin of the "Kaposi's sarcoma belt". Int J Cancer (2010) 1.18
Does partner selection contribute to sex differences in sexually transmitted infection rates among African American adolescents in San Francisco? Sex Transm Dis (2006) 1.16
Good performance of rapid prostate-specific antigen test for detection of semen exposure in women: implications for qualitative research. Sex Transm Dis (2009) 1.16
Reducing unplanned pregnancy and abortion in Zimbabwe through postabortion contraception. Stud Fam Plann (2002) 1.16
Novel strategies implemented to ensure high participant retention rates in a community based HIV prevention effectiveness trial in South Africa and Zimbabwe. Contemp Clin Trials (2009) 1.15
Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. PLoS Med (2012) 1.15
Qualitative assessment of venues for purposive sampling of hard-to-reach youth: an illustration in a Latino community. Sex Transm Dis (2004) 1.15
Advance provision of emergency contraception for pregnancy prevention: a meta-analysis. Obstet Gynecol (2007) 1.13
Consistent condom use in married Zimbabwean women after a condom intervention. Sex Transm Dis (2008) 1.13
Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa. PLoS One (2012) 1.13
HIV prevention research: taking stock and the way forward. AIDS (2010) 1.13
Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy. PLoS One (2013) 1.11